Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in five FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, rheumatoid arthritis, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

 

NASDAQ REGN

$386.96 7.18 (1.82)%

High 397.21 Low 386.47 Volume 414,291 Market Cap 40.31B
03/30/17 12:15 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Financial information

NEWSROOM

  • Mar 28

    Regeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXENT® (dupilumab) Approval

    Read on
  • Mar 28

    Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis

    Read on

EVENTS

  • Dupixent Approval Call
    Mar 28, 2017 | 4:00 PM ET

  • ACC 2017
    Mar 17, 2017

Events & Presentations

NASDAQ REGN

$386.96 7.18 (1.82)%

High 397.21 Low 386.47 Volume 414,291 Market Cap 40.31B
03/30/17 12:15 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Stock information

Financial information